RIPK1 and COVID-19: In addition, the activation of RIPK1 has also been implicated in mediating a variety of inflammatory diseases.5,24 For example, RIPK1 has been implicated in mediating the production of proinflammatory cytokines by interacting with NSP12 in COVID-19.25 Primidone has been suggested to inhibit COVID-19-associated cytokine release syndrome (CRS).10 Thus, the effect of primidone on the treatment of other inflammatory diseases may also be considered.